New scientific paper further confirms osteointegration of OssDsign Cranial PSI implants
OssDsign AB (publ) (“OssDsign” or the “Company”) today announced that independent researchers from Uppsala University Hospital, Sweden, have published a scientific paper in Journal of Neurosurgery describing bone integration in patients implanted with OssDsign Cranial PSI. Samples from four studied patients consistently show vascularized bone, integrating the OssDsign implant with surrounding native bone. This reaffirms the positive findings presented in previously published papers and further strengthens the benefits of OssDsign’s custom-made calcium phosphate implants.
Patients undergoing cranioplasty – the surgical repair of a bone defect in the skull – often suffer from complications. Reported rates of implant failure ranges from 10 to 30 percent and the risk of developing surgical site infections is high. Innovative implants, like OssDsign Cranial PSI, can decrease the risk for implant failure by improving osteointegration, thereby reducing the risk of foreign body reaction.
The research group at Uppsala University Hospital observed bone and blood vessel formation in the implants in all four studied patients. The integration occurred as effectively in the central parts of the implant as in the bone-adjacent parts. In one of the cases the full implant was removed due to a recurrent tumor, but in the three other cases the implants remain in place without signs of implant failure after 33, 36 and 50 months, respectively.
The researchers conclude that early and sustained osteointegration of OssDsign implants in cranioplasty occurs and should confer benefits for patients in need of the procedure.
“We are very encouraged by the case series from this independent clinical research group as they once again confirm bone and blood vessel formation integrating OssDsign’s implants with the surrounding bone. The ability of the implants to allow for regeneration of bone is a likely contributor to the low observed rate of complications showed in our recently presented updated outcome data from more than 1,000 cranioplasty procedures.” says Morten Henneveld, CEO of OssDsign.
Read the full article in Journal of Neurosurgery here.
For further information, please contact:
Morten Henneveld, CEO, OssDsign AB
Tel: +46 73 382 43 90, email: [email protected]
Erik Penser Bank AB is the company’s Certified Adviser. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: [email protected]
OssDsign’s vision is to provide regenerative solutions to all patients with cranial or spinal bone defects, so they can be restored and healed as naturally as possible. Driven by a commitment to give patients back the lives they deserve, OssDsign collaborates with surgeons to engineer better healing by integrating biomaterials with clinical design. Headquartered in Sweden, OssDsign supplies hospitals worldwide with implants for use in cranial reconstructions and other orthopaedic surgery applications.
BioStock: Cyxone i samarbete med ledande expert inom ledgångsreumatism
Bioteknikbolaget Cyxone förbereder läkemedelskandidaten Rabeximod för nästa kliniska steg.Nyligen tillkännagavbolaget ett samarbete med professor Costantino Pitzalis, en världsledande expert som omdefinierar klinisk prövningsdesign inom ledgångsre...
I-Tech AB får en ramorder värd 53 MSEK från Chugoku Marine Paints
Ordern från Chugoku Marine Paints syftar till att säkra framtida leveranser för befintliga och nyligen introducerade bränslebesparande antifoulingprodukter runt om i världen. Ramordern utgör ett minimi-åtagande för leveranser och specifika order är att...
I-Tech AB receives a frame order worth 53 MSEK from Chugoku Marine Paints.
The order is placed by Chugoku Marine Paints as a measure to secure supply in the expansion of existing and newly introduced fuel saving antifouling products around the world. This frame order constitutes a minimum undertaking and specific orders, and timing of such, is to be clarified further on wi...
Nexstim granted authorization for commercial distribution of NBS system in Australia
Nexstim’s NBS System is the only FDA cleared system based on navigated Transcranial Magnetic Stimulation (nTMS) for non-invasive mapping of the speech and motor cortices of the brain. The NBS system is used, for example, after a patient has had a diagnosis of a brain tumor or other disorder and when...